Medicine status
Orforglipron (Foundayo) in Canada
Where the orforglipron pill stands in Canada, what the trials found, and what nobody knows yet.
Orforglipron is a once-daily pill that acts on the GLP-1 receptor, the same target as semaglutide (Ozempic, Wegovy). It is made by Eli Lilly. In the United States it is sold as Foundayo. This page sets out where it stands in Canada, what the trials found, and what is still unknown.
As of 4 October 2026, orforglipron is not authorized in Canada. There is no Canadian product to prescribe or dispense, and anything sold online as orforglipron is not an authorized product. Nothing on this page is advice about whether anyone should take it.
Where it stands in Canada
- Under review. Health Canada has been reviewing an orforglipron submission from Eli Lilly Canada since January 2026 R43-C01.
- Not authorized. There is no orforglipron product in Health Canada's Drug Product Database or Notice of Compliance records R43-C02.
- Possibly for diabetes first. Health Canada's list names only the drug class. A published drug profile says the Canadian submission is for type 2 diabetes R43-C03. If that is right, a first Canadian approval may cover diabetes and not weight management. Health Canada has not said.
- No Canadian brand, price or date. We found no Canadian brand name, price or launch date in the sources checked.
In other countries
The US FDA approved orforglipron as Foundayo on 1 April 2026, for adults with obesity, or overweight with a weight-related health problem, alongside diet and exercise R43-C04. Lilly says it has applied in more than 40 countries R43-C04. A US approval does not make a medicine available in Canada; that takes a Health Canada decision.
How much weight did people lose in the trials?
The two main weight trials lasted 72 weeks. People without diabetes lost more than people with type 2 diabetes, which is also what happens with semaglutide and tirzepatide.
| Trial | Who took part | Weight change by daily dose | With placebo |
|---|---|---|---|
| ATTAIN-1 | Adults with obesity, no diabetes | -7.5% (6 mg), -8.4% (12 mg), -11.2% (36 mg) R32-C61 | -2.1% |
| ATTAIN-2 | Adults with type 2 diabetes and BMI 27 or more | -5.1% (6 mg), -7.0% (12 mg), -9.6% (36 mg) R33-C07 | -2.5% |
These are averages. Some people lost much more and some lost little. The trial doses are not the US tablet strengths, so the numbers do not map one to one onto a prescription.
Side effects and safety
- Stomach side effects were the main reason people stopped. In ATTAIN-1, 5.3% to 10.3% of people on orforglipron stopped because of side effects, against 2.7% on placebo R32-C62. In ATTAIN-2 it was 6.1% to 9.9% against 4.1% R33-C08.
- Heart safety. ACHIEVE-4 compared orforglipron with insulin glargine in 2749 adults with type 2 diabetes and heart or kidney disease. Major heart events happened in 4.2% on orforglipron and 5.0% on insulin glargine R33-C09. The trial was built to rule out a large increase in heart risk, not to prove a benefit; see the ACHIEVE-4 page.
All the orforglipron studies on this site
- Orforglipron phase 2: a daily GLP-1 pill for weight loss
- ATTAIN-1: weight loss over 72 weeks
- ATTAIN-2: weight loss in type 2 diabetes
- ATTAIN-MAINTAIN: switching from tirzepatide or semaglutide to orforglipron
- ACHIEVE-1: early type 2 diabetes
- ACHIEVE-3: orforglipron versus oral semaglutide
- ACHIEVE-4: heart safety in type 2 diabetes
For the medicines that are authorized in Canada now, see Wegovy, Ozempic, Mounjaro and Zepbound compared.
Common questions
Is orforglipron approved in Canada?
No. As of 4 October 2026 it is under review at Health Canada, which received the submission in January 2026 R43-C01 R43-C02.
What is Foundayo?
Foundayo is the US brand name of orforglipron, approved by the US FDA on 1 April 2026 for weight management in adults R43-C04. It has no Canadian brand name yet.
How much weight can you lose with orforglipron?
In ATTAIN-1, average weight change over 72 weeks was -7.5% to -11.2% depending on the dose, against -2.1% with placebo R32-C61. People with type 2 diabetes lost less: -5.1% to -9.6% in ATTAIN-2 R33-C07.
When will orforglipron be available in Canada?
Nobody can say yet. Health Canada does not publish review timelines, and one published profile says the Canadian submission is for type 2 diabetes R43-C03.
Evidence records behind this page
Each record is a row in the clinical evidence file, taken from the published paper named above. The caution column is the limit the researcher recorded for that number.
This table scrolls sideways.
| Record | What the paper reports | Type | Population | Caution | Source |
|---|---|---|---|---|---|
| R32-C61 | In ATTAIN-1, 72-week average weight change was -7.5%, -8.4% and -11.2% with orforglipron 6, 12 and 36 mg, versus -2.1% with placebo. | direct evidence | Adults with obesity without diabetes | Studied as investigational obesity therapy; current Canadian authorization status not verified. Abstract-only; adults without diabetes. | PubMed 40960239 |
| R33-C07 | In ATTAIN-2 (1613 adults with type 2 diabetes and BMI at least 27), 72-week body-weight change was -5.1%, -7.0% and -9.6% with orforglipron 6, 12 and 36 mg daily versus -2.5% with placebo; treatment differences were -2.7 (95% CI -3.7 to -1.6), -4.5 (-5.5 to -3.6) and -7.1 (-8.2 to -6.1). | direct evidence | Adults with T2D (HbA1c 7 to 10%) and BMI at least 27 | Treatment-regimen estimand primary; efficacy estimand supportive but not reported numerically in abstract. Manufacturer-funded. Abstract-only. As of October 2026 orforglipron is not authorized in Canada (under Health Canada review since January 2026); US FDA approved it 2026-04-01 as Foundayo for weight management. | PubMed 41275875 |
| R32-C62 | Adverse events caused treatment discontinuation in 5.3 to 10.3% across orforglipron dose groups and 2.7% with placebo in ATTAIN-1. | direct evidence | Adults with obesity without diabetes | Studied as investigational obesity therapy; current Canadian authorization status not verified. Abstract-only; adults without diabetes. | PubMed 40960239 |
| R33-C08 | In ATTAIN-2, treatment discontinuation due to adverse events (mainly gastrointestinal) occurred in 6.1% to 9.9% across orforglipron dose groups versus 4.1% with placebo. | direct evidence | Adults with T2D (HbA1c 7 to 10%) and BMI at least 27 | Dose-specific rates not given in abstract. Abstract-only. As of October 2026 orforglipron is not authorized in Canada (under Health Canada review since January 2026); US FDA approved it 2026-04-01 as Foundayo for weight management. | PubMed 41275875 |
| R33-C09 | In ACHIEVE-4 (2749 adults with type 2 diabetes and established cardiovascular or chronic kidney disease), MACE-4 occurred in 4.2% (57 of 1358) with orforglipron versus 5.0% (67 of 1343) with insulin glargine over a median 2 years (HR 0.84; 95% CI 0.59 to 1.20), meeting the prespecified non-inferiority margin of 1.8. | direct evidence | Adults with T2D at increased cardiovascular risk, HbA1c 7.0 to 10.5%, BMI at least 25 | Open-label; active comparator is insulin glargine, not placebo or a GLP-1 medicine. Non-inferiority margin 1.8 rules out only a large increase; does not show superiority. Orforglipron given as capsule up to 36 mg (stated equivalent to 17.2 mg tablet). Abstract-only. As of October 2026 orforglipron is not authorized in Canada (under Health Canada review since January 2026); US FDA approved it 2026-04-01 as Foundayo for weight management. | PubMed 42815506 |
Sources for this page
Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.
This table scrolls sideways.
| Claim | What the source says | Source | Source date | Accessed | Label |
|---|---|---|---|---|---|
| R43-C01 | Health Canada's new drug submissions under review list shows orforglipron calcium, therapeutic area Drugs used in diabetes, accepted for review in January 2026, sponsor Eli Lilly Canada Inc. | canada.ca/en/health-canada/services/drug-health-product-r... | page modified 2026-09-24 | 2026-10-04 | regulator-confirmed |
| R43-C02 | No orforglipron product appears in the Health Canada Drug Product Database or the Notice of Compliance database as of 2026-10-01; it is not authorized in Canada. | health-products.canada.ca/api/drug/activeingredient/?lang... | NOC database entries to 2026-10-01 | 2026-10-04 | regulator-confirmed |
| R43-C03 | A peer-reviewed drug profile (Drugs, 2026-07-21) reports that orforglipron was submitted in the EU for long-term weight management and type 2 diabetes, in Japan for weight management, and in Canada for type 2 diabetes. | doi.org/10.1007/s40265-026-02363-5 | 2026-07-21 | 2026-10-04 | peer-reviewed |
| R43-C04 | The US FDA approved orforglipron as Foundayo on 2026-04-01 for adults with obesity, or overweight with weight-related medical problems, with diet and exercise; tablets of 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. Lilly says it has submitted orforglipron in more than 40 countries and plans to launch in each shortly after approval. | investor.lilly.com/news-releases/news-release-details/fda... | 2026-04-01 | 2026-10-04 | company self-report |